|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 672.15 USD | -0.67% |
|
+1.15% | -12.92% |
| 07-20 | Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating | MT |
| 07-16 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
| Market Cap | 68.85B 60.33B 55.79B 51.29B 96.94B 6,639B 98.44B 666B 261B 3,246B 259B 253B 11,187B | P/E 2026 * |
17.6x | P/E 2027 * | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 61.02B 53.48B 49.45B 45.46B 85.92B 5,885B 87.26B 590B 231B 2,877B 229B 224B 9,916B | EV / Sales 2026 * |
3.84x | EV / Sales 2027 * | 3.31x |
| Free-Float |
72.33% | Yield 2026 * |
0.58% | Yield 2027 * | 0.66% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | -0.67% | ||
| 1 week | +1.15% | ||
| Current month | +7.80% | ||
| 1 month | +10.20% | ||
| 3 months | -10.45% | ||
| 6 months | -8.31% | ||
| Current year | -12.92% |
| 1 week | 648.66 |  | 691.13 |
| 1 month | 594.9 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/2/26 A | Sell | Director | -200 | 0.0002% | ||
| 5/1/26 A | Sell | Director | -100 | 0.0001% | ||
| 4/1/26 A | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | +1.15% | +23.89% | -6.52% | 68.85B | |
| -0.54% | +0.38% | +36.12% | +192.81% | 52.13B | |
| -3.65% | +34.50% | +34.50% | +34.50% | 43.46B | |
| -0.58% | -0.23% | -52.36% | -53.82% | 41.24B | |
| -2.93% | +0.40% | +59.97% | -27.79% | 30.41B | |
| -3.77% | -12.86% | +90.31% | -52.47% | 24.53B | |
| -1.36% | -0.91% | +70.42% | +83.86% | 23.42B | |
| +3.99% | +3.12% | +3.87% | +200.81% | 19.75B | |
| +0.26% | -1.74% | +70.47% | +125.19% | 16.57B | |
| -0.76% | -5.97% | +73.64% | +134.36% | 15.95B | |
| Average | -0.64% | -1.45% | +41.08% | +63.09% | 33.63B | |
| Weighted average by Cap. | -0.92% | -0.69% | +32.63% | +50.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.88B 13.92B 12.87B 11.83B 22.36B 1,531B 22.71B 154B 60.22B 749B 59.63B 58.33B 2,580B | 17.65B 15.46B 14.3B 13.15B 24.85B 1,702B 25.23B 171B 66.92B 832B 66.26B 64.81B 2,867B |
| Net income | 3.99B 3.5B 3.23B 2.97B 5.62B 385B 5.7B 38.59B 15.13B 188B 14.98B 14.65B 648B | 5.03B 4.4B 4.07B 3.74B 7.08B 485B 7.19B 48.62B 19.06B 237B 18.87B 18.46B 817B |
| Net Debt | -7.82B -6.86B -6.34B -5.83B -11.01B -754B -11.19B -75.67B -29.67B -369B -29.37B -28.73B -1,271B | -10.51B -9.21B -8.52B -7.83B -14.8B -1,014B -15.03B -102B -39.87B -496B -39.48B -38.61B -1,708B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/07/26 | $672.15 | -0.67% | 606,745 |
| 17/07/26 | $676.69 | -0.33% | 648,400 |
| 16/07/26 | $678.94 | +2.18% | 730,245 |
| 15/07/26 | $664.45 | +1.27% | 555,419 |
| 14/07/26 | $656.12 | -1.05% | 477,991 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition